Abstract
Inadequate presentation of tumor antigens by host professional antigen–presenting cells (APCs), including dendritic cells (DCs), is one potential mechanism for the escape of tumors from the host immune system. Here, we show that human cancer cell lines release a soluble factor or factors that dramatically affect DC maturation from precursors without affecting the function of relatively mature DCs. One factor responsible for these effects was identified as vascular endothelial growth factor (VEGF). Thus, VEGF may play a broader role in the pathogenesis of cancer than was previously thought, and therapeutic blockade of VEGF action may improve prospects for immunotherapy as well as inhibit tumor neovasculature.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Loannides, C. & Whiteside, T. T cell recognition of human tumors: Implication for molecular immunotherapy of cancer. Clin. Immunol. Immunopathol 66, 91–106 (1993).
Cozzolino, F. et al. Characterization of cells from invaded nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphopro-liferative response. J. Exp. Med. 166, 303–318 (1987).
Belldegrun, A., Kasid, A., Uppenkamp, M., Topalian, S.L. & Rosenberg, S.A. Human tumor infiltrating lymphocytes: Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J. Immunol. 42, 4520–4526 (1989).
Gabrilovich, D., Ciernik, F. & Carbone, D.P. Dendritic cells in anti-tumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 170, 101–110 (1996).
Huang, A.Y.C. et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961–965 (1994).
Rock, K.L., Rothstein, L., Gamble, S. & Fleishacker, C. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J. Immunol. 150, 438–446 (1993).
Tan, K.C., Hosoi, J., Grabbe, S., Asahina, A. & Granstein, R.D. Epidermal cell presentation of tumor-associated antigens for induction of tolerance. J. Immunol 153, 760–767 (1994).
Watson, G. & Lopez, D.M. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J. Immunol. 155, 3124–3134 (1995).
Alcalay, J. & Kripke, M.L. Antigen-presenting activity of draining lymph node cells from mice painted with a contact allergen during ultraviolet carcinogenesis. J. Immunol. 146, 1717–1721 (1991).
Erroi, A. et al. IL1 and IL6 released by tumor-associated macrophages from human ovarian carcinoma. Int. J. Cancer 41, 65–68 (1989).
Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271–296 (1991).
Knight, S.C. & Stagg, A.J. Antigen-presenting cell types. Curr. Opin. Immunol. 5, 374–382 (1993).
Austin, J.M. The dendritic cell system and anti-tumor immunity. In Vivo 7, 193–202 (1993).
Zitvogel, L. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87–97 (1996).
Mayordomo, J.I. et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297–1302 (1995).
Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52–58 (1996).
Tas, M., Simons, P., Balm, F. & Drexhage, H. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: In vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol Immunother. 36, 108–114 (1993).
Reynolds, N.J. et al. Down-regulation of Langerhans cell protein kinase C-beta isoenzyme expression in inflammatory and hyperplastic dermatoses. Br. J. Dermatol 133, 157–167 (1995).
Bergfelt, L., Emilson, A., Lindberg, M. & Scheynius, A. Quantitative and three-dimensional analysis of Langerhans cells in basal cell carcinoma: A comparative study using light microscopy and confocal laser scanning microscopy. Br. J. Dermatol 130, 273–280 (1994).
Toriyama, K., Wen, D.R., Paul, E. & Cochra, A.J. Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J. Invest. Dermat. 100, 269S–273S (1993).
Gabrilovich, D.I., Nadaf, S., Corak, J., Berzofsky, J.A. & Carbone, D.P. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol 170, 111–120 (1996).
Caux, C., Dezutter-Dambuyant, C., Schmitt, D. & Banchereau, J. GM-CSF and TNF-α cooperate in the generation of dendritic cells. Nature 360, 258–261 (1992).
Reid, C.D., Stackpoole, A., Meager, A. & Tikerpae, J. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J. Immunol 149, 2681–2688 (1992).
Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109–1118 (1994).
Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M. & Heldin, C.-H. Different signal transduction properties of KDR and FLT1, two receptors for vascular endothelial growth factor. J. Biol Chem. 269, 26988–26995 (1994).
Szabolcs, P. et al. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 87, 4520–4530 (1996).
Reid, C.D.L. et al. Identification of hematopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood. Blood 76, 1139–1149 (1990).
Roth, P. & Stanley, E.R. The biology of CSF-1 and its receptor. Curr. Topics Microb. Immunol. 181, 141–155 (1992).
Rozenzwajg, M., Canque, B. & Gluckman, J.C. Human dendritic cells differentiation pathway from CD34+ hematopoietic precursor cells. Blood 87, 535–544 (1996).
Leung, D.W., Cachianes, G., Kuang, W.-J., Goeddel, D.V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–1309 (1989).
Connolly, D.T. et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84, 1470–1478 (1989).
Takeshita, S. et al. Therapeutic angiogenesis: A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit is chemic hind limb model. J. Clin. Invest. 93, 662–670 (1994).
Ferrara, N., Houck, K., Jakeman, J. & Leung, D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev. 13, 18–32 (1992).
Kondo, S., Asano, M., Matsuo, K., Ohmori, I. & Suzuki, H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochem. Biophys. Acta 1221, 211–214 (1994).
Takano, S. et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56, 2185–2190 (1996).
Shen, H. et al. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood 81, 2767–2773 (1993).
Hoehn, G.T. et al. Tnk1: A novel intracellular tyrosine kinase gene isolated from human umbilical cord CD34+/Lin−/CD38− stem/progenitor cells. Oncogene 12, 903–913 (1996).
Katoh, O., Tauchi, H., Kawaishi, K., Kimura, A. & Satow, Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55, 5687–5692 (1995).
Broxmeyer, H.E. et al. Myeloid progenitor cells regulatory effects of vascular endothelial cell growth factor. Inter. J. Hematol. 62, 203–215 (1995).
Axelsson, K. et al. Tumor angiogenesis as a prognostic assay for invasive due tal breast carcinoma. J. Natl. Cancer Inst. 87, 997–1008 (1995).
Bossi, P. et al. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 55, 5049–5053 (1995).
Bochner, B.H. et al. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst. 87, 1603–1612 (1995).
Gazdar, A.F. & Oie, H.K. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46, 6011–6012 (1986).
Bhardwaj, N. et al. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J. Clin. Invest. 94, 797–807 (1994).
Hayhoe, F.G.J. & Quaglino, D. Haematological Cytochemistry. (Churchill Livingston, London, 1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gabrilovich, D., Chen, H., Girgis, K. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2, 1096–1103 (1996). https://doi.org/10.1038/nm1096-1096
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm1096-1096